Serigen Mediproducts Bags INR 10 Cr Funding to Advance Regenerative Medicine

This financial injection will bolster the company’s efforts to develop innovative tissue regeneration products utilizing silk proteins.

Serigen Mediproducts, a Pune-based biomedical manufacturing company, has successfully raised INR 10 Cr in a funding round led by IAN Alpha Fund and Colossa Ventures. 

Reportedly, both the existing and new angel investors participated in the funding round.

This financial injection will bolster the company’s efforts to develop innovative tissue regeneration products utilizing silk proteins.

Further, the newly acquired funds will also be allocated to completing clinical trials and obtaining regulatory approvals in India and globally for Serigen’s product lines.

Anuya Nisal, founder and CEO of Serigen Mediproducts, said, “We are delighted to welcome new institutional investors like the IAN Alpha Fund in this round of funding and thank them for their faith in the company. We are also grateful to existing/incoming angel investors and Colossa Ventures for their support of Serigen. The funding proceeds will be used to complete clinical trials, obtain Indian and global regulatory approvals for our product lines, accelerate sales and marketing efforts, and build and strengthen our team.” 

Additionally, the company plans to accelerate its sales and marketing initiatives and expand its team to support growth. 

This investment aligns with Serigen’s mission to advance regenerative medicine through dedicated research and development.

Serigen Mediproducts has developed three key products to improve wound care and surgical patient outcomes. 

Serioss serves as an osteoconductive bone void filler, facilitating bone regeneration. Seriderm is an absorbent wound dressing crafted with silk protein to enhance the wound healing process. 

Serimat, a silk protein mesh, is utilized in various reconstructive surgeries, including breast reconstruction, abdominal wall reconstruction, and dural repair. 

These products leverage the unique properties of silk protein to provide effective solutions for medical professionals, enhancing tissue regeneration and patient recovery.

Commenting on the funding, Ashu Suyash, founder and CEO of Colossa Ventures, said, “Serigen’s innovative approach to leveraging silk proteins for critical care solutions aligns with our mission to back women-led ventures that are poised for scalable growth and can also drive meaningful impact. We look forward to seeing Serigen's products transform patient care and set new standards in the medical field.’’